of primitive and mature myeloid progenitors in mobilized PB CD34+ cells was similar t o their steady-state counterparts, but the percentages of CD34+ cells expressing CD10 or CD19 were lower ( P < .0028). Although steady-state PB and chemotherapy-mobilized CD34+ cells generated fewer CFU-GM at day 21 than G-CSF-mobilized and steady-state BM CD34+ cells ( P < .0449), the generation of nucleated cells and CFU-GM were otherwise comparable. The presence of increased or comparable numbers of hematopoietic progenitors within PB collections with equivalent proliferative capacity to BM CD34' cells is not unexpected given the rapid and complete hematopoietic reconstitution observed with mobilized PB. However, all four types of mobilized PB CD34' cells are different from steady-state BM CD34' cells in that they express less c-kit ( P < .0002) and CD71 ( P < .04) and retain less rhodamine 123 ( P < .0001). These observations are novel and suggest that different mobilization protocols may act via similar pathways involving the down-regulation of c-kit and may be independent of cell-cycle status. is the reverse of the process of homing seen during fetal development or after stem cell infusion in transplantation. Despite the increasing understanding of progenitor/stroma interactions, the mechanisms of mobilization remain undefined.
Autotransplantation using mobilized PB is associated with more rapid hematopoietic reconstitution (HR), lower requirement for blood products and parenteral antibiotics, and shorter hospitalization compared with BM transplantaeloid progenitor cells (granulocyte-macrophage colony-stimulating factor; CFU-GM) infused correlates with the rate of neutrophil and platelet recovery.".'2 However, the CFU-GM dose infused is only a surrogate measure of HR capacity and is not necessarily predictive for individual patients.I3 In addition, murine transplantation studies suggest that posttransplant recovery is polyphasic with different progenitors responsible for different phases of r e~0 v e r y . l~ Early murine and human studies suggested that there are few, if any, longterm marrow repopulating cells (LTMRCs) in circulation during steady state,'"I6 whereas recent data in the murine system suggests that LTMRCs are present in cyclophosphamide or G-CSF-mobilized PB.17"9 Furthermore, the presence of preprogenitors in mobilized PB CD34' cells has been shown by the sustained production of nascent CFU-GM in stromal-free liquid culture for at least three weeks.'" There is also increasing evidence that the HLA-DR-, CD33 , CD38-, Rhodamine 123d"i', and c-kit' subsets of human BM CD34' cells contain the most primitive hematopoietic Recently, long-term culture initiating cells (LTCICs) have been documented at low levels in normal human PB .25,2"
These findings suggest that an assessment of the phenotype and proliferative capacity of PB CD34' cells would describe the spectrum of hematopoietic stedprogenitor cells in mobilized PB. For personal use only. on January 1, 2018. by guest www.bloodjournal.org From valuable insights into the mechanisms responsible for mobilization of hematopoietic progenitor cells.
This report describes the expression of activation and lineage-associated antigens on mobilized PB CD34+ cells and their proliferative capacity. Cells from patients treated with the four most commonly used PB stem cell mobilization protocols were studied: recovery phase after myelosuppressive chemotherapy alone, recovery phase after chemotherapy and GM-CSF or G-CSF, and during administration of G-CSF alone. Our data show that CD34+ cells mobilized using different stimuli were remarkably similar to each other and contained similar proportions of mature and primitive progenitors to those in steady-state CD34+ cells. However, all four types of mobilized PB CD34+ cells differ from their steady-state counterparts in their lower expression of c-kit and CD71 and in their low rhodamine-l23 (Rh123; Molecular Probes Inc, Eugene, OR) retention. The consistent downregulation of c-kit on CD34+ cells in mobilized PB compared with the levels on steady-state BM CD34+ cells is particularly striking. While the significance of this observation remains to be determined, it is tempting to speculate that this may play a direct and pivotal role in the different mobilization methods studied.
MATERIALS AND METHODS

PBSC Mobilization Protocols
Myelosuppressive chemotherapy with or without cytokines. Patients received cyclophosphamide 4 or 7 g/m2 as previously reand depending on enrollment into clinical study protocols received GM-CSF, G-CSF, or no hematopoietic growth factors. GM-CSF was administered daily in the form of human recombinant GM-CSF (Leucomax; Sandoz, Basel, Switzerland) at 5 pg/kg/d subcutaneously from day 2 onward until a maximum of six aphereses were completed. G-CSF was administered in the form of human recombinant G-CSF (Filgrastim; Amgen, Thousand Oaks, CA) at 5pg/kg/d subcutaneously daily from day 2 onward until a maximum of four aphereses were completed. Leukapheresis was commenced when the leukocyte count reached 1 X 109/L.
A number of patients underwent mobilization as part of planned chemotherapy. One patient with lymphoma received DHAP2* and G-CSF at 5 pg/kg/d by subcutaneous injection. One patient with breast carcinoma received cyclophosphamide 4 g/m' with epirubicin 200 mg/m2 and G-CSF at 5 pg/kg/d by subcutaneous injection. Three other patients received the same doses of cyclophosphamide and epirubicin as well as GM-CSF at 5 pg/kg/d by subcutaneous injection.
G-CSF. Patients received human recombinant G-CSF at 12 pg/ kg/d by continuous subcutaneous infusion over 6 days as previously reported? Leukapheresis was performed on days 5, 6, and 7 using a Fenwal CS3000 continuous flow blood cell separator (Baxter Healthcare Corp, Deerfield, IL) as previously rep~rted.'~ The apheresis product was processed by separation on a Lymphoprep density gradient (1.077 g/dL, Nycomed Pharma As, Oslo, Norway) and washed three times by centrifugation at 400g before cryopreservation in 10% dimethyl sulfoxide and 20% autologous plasma in liquid nitrogen."
Normal Subjects
Normal volunteers under the age of 40 years enrolled in a normal donor program providing BM and PB. This study has been approved by the Human Ethics Committee of the Royal Adelaide Hospital, Adelaide.
Preparation of Cells
BM from volunteer donors was collected into preservative-free heparin and separated on a Lymphoprep density gradient. Lightdensity cells were washed twice in wash buffer: Hanks balanced salt solution (HBSS) with 5% fetal calf serum (FCS; Commonwealth Serum Laboratories, Parkville, Victoria, Australia) and resuspended at 1 x IO7 cells/mL. Similarly, light-density mononuclear cells from apheresis products were washed and resuspended at 1 X lo7 cells/ mL. Cryopreserved samples were separated over Lymphoprep, washed, and also resuspended at 1 X lo7 cells/mL. Steady-state PB mononuclear cells (PBMNCs) were collected from five normal subjects after 1 hour of apheresis on the Fenwal CS3000. After Lymphoprep separation, CD34' cells within the light-density fraction were enriched using a CEPRATE avidin column (Cellpro; Bothell, Seattle, WA) as previously described." Without this enrichment step, it was not possible to perform reliable immunophenotyping in steady-state PBMNCs because of the low frequency of CD34+ cells (0.05% to 0.1%).
Immunophenotyping and Fluorescence-Activated Cell Sorting (FACS)
Enumeration of CD34+ cells in cell suspensions was performed as described by Sutherland et a1.4' Briefly, the cell suspension was stained simultaneously with a fluorescein isothiocyanate (FITC)-conjugated CD45 antibody (HLe-1, Becton Dickinson, Mountain View, CA) and a phycoerythrin (PE)-conjugated CD34 antibody (HPCA-2-PE). The incidence of CD34' cells was determined by "back gating" for CD45 expression and side scatter where true CD34' events were characterized by low-density CD45 expression and low side scatter.
The expression of activation or lineage-associated antigens on CD34' cells was determined by incubation with antibody against CD34 together with antibody to the specific marker. Thus cells were incubated for 40 minutes at 4°C with 8G12-FITC (anti CD34: 5 pg/ L X lo6 cells [gift from Dr J. Bender, Baxter Healthcare Corp]) alone or with one of the following PE-conjugated monoclonal antibodies, HLA-DR, LeuM9 (CD33), Leu17 (CD38), Leu12 (CD19), LeuM7 (CD13), or IgGPE. Cells were also stained with HPCA-2-PE (CD34) alone or with one of the following FITC conjugates: LeuMl (CD15), CDllb (Serotec Ltd, Oxford, UK), CDIO, CD71, and Leu9 (CD7). Unless otherwise stated, all antibodies were supplied by Becton Dickinson and used as recommended by the manufacturer.
Expression of c-kit was determined by incubating cells with the IgM CD34 antibody 12.8 (gift from Dr R. Andrews, Seattle, WA) and the IgG antibody YB5.B831 followed by the isotype-specific second antibodies conjugated to FITC and PE, respectively (Southem Biotechnology, Birmingham, AL). When steady-state PB was processed on the CEPRATE device then CD34' cells were labeled by either a FITC-or PE-conjugated goat-antimouse IgM antibody and expression of other antigens determined by using IgG-specific antibodies conjugated to either PE or FITC as appropriate.
After immunolabeling, cells were washed twice then resuspended in FACS Fixative (2% vol/vol formaldehyde in Dulbecco's phosphate-buffered solution) unless they were to be sorted. Samples were analyzed within two days using a Coulter Profile I1 flow cytometer (Coulter Electronics, Miami, FL) with standard optical configuration and an argon laser emitting 488 nm at 15 mW. Listmode data from 100,000 events was collected and analyzed to determine the proportion of CD34+ cells expressing the relevant marker.
Rh123 staining was performed according to the method described by Bertoncello." Briefly, 2 X lo6 light-density cells were incubated for 45 minutes at 37°C in 5 mL of wash buffer containing Rh123 at 0.1 pg/mL. After two washes, excess internalized Rh123 was For personal use only. on January 1, 2018. by guest www.bloodjournal.org From removed by incubating the cells with wash buffer for 15 minutes at 37°C. The Rhl23-labeled cells were then incubated with PE-conjugated HPCA-2 as described above. Analysis was performed on a Coulter Profile I1 flow cytometer within 30 minutes of staining. At least 100,000 cells were examined and the distribution of Rh123 uptake by CD34' cells was determined by analysis of CD34' cells discriminated on the PE-side-scatter dot plot.
Pre-Progenitor (Pre-CFU) Assay
This assay has been reported previously2" and is an adaption of the 4-day suspension culture system described by Iscove et al? 3 The generation of nascent CFU-GM by FACS-sorted CD34' cells was used as an index of pre-CFU. Briefly, after immunolabeling, cells were resuspended in HBSS/5% FCS then CD34' cells were sorted into Iscove's minimal essential medium (IMDM) using a FACSGI?'"~ (Becton Dickinson). Postsort purity checks were performed routinely.
Sorted CD34' cells were resuspended at 1 X lo3 cells/mL in Pre-CFU medium (IMDM supplemented with 30% FCS, 1% bovine serum albumin, 3 mmol/L L-glutamine and 5 X m o l n pmercaptoethanol). Six replicate l-mL suspension cultures were established in 24-well plates (Nunc, Intermed, Denmark) in the presence of six recombinant human hematopoietic growth factors (HGFs), all at 10 ng/mL: IL-l, IL-3, IL-6, GM-CSF, G-CSF, and stem cell factor (SCF; Amgen, Thousand Oaks, CA). This combination of HGF was chosen because it gives rise to the highest CFU-GM generation compared with any other combinations using any five or fewer HGFs or single HGF."
The cultures were incubated at 37°C in 5% CO2 in a fully humidified atmosphere. On day 7, three wells were harvested, counted, and cultured in a CFU-GM assay while the remaining three wells were refed with IO ng/mL of each of the six HGF. On day 14, the three remaining wells were harvested for cell counts and CFU-GM assay, and one fifth of the contents of each well were replated into new wells together with another 10 ng/mL of each of the six HGF. These triplicate cultures were again harvested at day 21 with a proportion of the cells cultured for CFU-GM and a proportion replated in pre-CFU assay with fresh media and six HGF until day 28. At each time point of sampling, the total number of nucleated cells and CFU-GM present was determined after accounting for culture dilution and the number of cellslplate in the CFU-GM assay.
CFU-GM Assay
Triplicate l-mL cultures were established in 35-mm plates in 0.9% methyl cellulose in IMDM supplemented with 30% FCS and 3 mmoV L L-glutamine as previously reported.% Cultures were stimulated by the same six-growth-factor combination as in the pre-CFU assay, and aggregates of 40 or more cells present after 14 days were scored as CFU-GM.
Statistics
Multiple group comparisons were performed using analysis of variance (ANOVA) and group-group comparisons were based on the Fisher PLSD (Fisher Scientific CO, Boston, MA). X' statistics was used for nominal variables. Mean 2 1 SE was used unless otherwise specified.
RESULTS
Cells collected by apheresis were studied from five patients (14 apheresis samples) who received myelosuppressive chemotherapy (Cm), three patients (3 apheresis samples) who received Cm + GM-CSF, three patients (3 apheresis samples) who received Cm + G-CSF, and eight patients (8 apheresis samples) who received G-CSF alone. Cells from BM and the PB of five normal individuals were used as steady-state controls. Details of the patients and normal donors and the percentage of CD34' cells in the cell suspensions analyzed are listed in Table I .
Phenotype o j CD34' Cells
The immunophenotype of CD34' cells from the four mobilization protocols and from steady-state PB and BM are shown in Table 2 . For the majority of antigens studied, the proportion of antigen-positive or antigen-negative cells could be accurately enumerated. This is shown by representative examples in Fig 1 for the expression of CD38, HLA-DR, and CD10 on CD34' cells. However the expression of CD33, CD71, and c-kit on PB CD34' cells was continuous from low to high levels of expression without discrete positive and negative populations (Fig 2) . Thus, the percentage values shown for these are arbitrary values that indicate the relative number of cells with antigen expression above that of the 99th percentile of the isotype control. An alternative parameter of the expression is the peak shift in fluorescence intensity of cells stained for CD33, CD7 1, and c-kit as compared with the peak fluorescence for cells stained with an isotype control. This is also reported in Table 2 . Cells with a stronger antigen expression have a higher peak-shift value.
Activation Status (CD38, HLA-DR, Rhodamine, and CD71)
Eighty-eight percent 2 3.0% of G-CSF-mobilized CD34' cells expressed CD38, significantly lower than that of other CD34+ cells, (means ranged from 96.1% to 99.0%; oneway ANOVA, P = ,0032; Fisher's PLSD comparing G-CSF mobilized CD34' cells with other CD34' cells, P values ranged from .OW7 to .0081). This lower expression was seen both in patients who had and who had not received prior chemotherapy. Eighty-nine percent 2 4.8% of G-CSF-mobilized CD34' cells expressed HLA-DR, lower than the other CD34+ cells (means ranged from 94.3% to 98.4%), but the difference did not reach statistical significance.
The intensity of Rh123 staining of CD34' cells was expressed as bright, intermediate, or low based on a comparison with the monocytes (which exhibit high Rh123 staining) in the CD34-population from the same specimen (Fig 3) . BM CD34' cells were predominantly Rh123bngh' (919) and steady-state PB CD34' cells were either Rh123'"'ermed'a'e (21 7) or I "" (5/7), whereas 13/14 of mobilized CD34' cells were Rhodamine 123'"" and 1/14 was Rh123i"'e'm"d'a'e . These differences between the groups were statistically significant (x2 test, P = .0001). Post-hoc analysis showed that BM CD34' cells were significantly more Rh123b"gh', whereas the mobilized CD34' cells were significantly more Rh123'"". The pattern of CD71 expression was quite different between the different types of CD34' cells. BM CD34' cells consisted of three populations: CD7 1 br'gh', CD7 Id'"', and CD7 1 with the bright population predominant. Steady-state PB CD34+ cells also consisted of the same three populations, but the dim population was the predominant population. MObilized CD34' cells were mostly CD71 -and most of the positive population was CD7 1
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From to .0048). The difference in peak shift was also significant (one-way ANOVA, P = .0232). There was no significant (means ranged from 0.1% to 1.2% compared with 18.8%; one-way ANOVA, P = .0085; Fisher's PLSD P values ranged from .W15 to .0028), but no different from that of steady-state PB (8.9% ? 2.7%). In the steady-state PB most CD34' CD10+ cells had high side-scatter characteristics suggesting that they were mostly monocytes. There was no significant difference in the expression of CD7 among the six types of CD34+ cells (means range from 0.5% to 4%).
c-kit
The expression of c-kit on PB CD34+ cells was significantly different from that on BM CD34+ cells (Fig 2) . Instead of well-defined c-kit' and c-kit-populations as in BM, most PB CD34' cells expressed low levels of c-kit. As a population, the intensity of expression was a continuum from very low to intermediate levels. The peak shift in c-kit expression was significantly higher on CD34+ cells from BM (5.2 2 0.6) than those on PB, steady phase or mobilized (means ranged from 0.6 to 2.1; one-way ANOVA, P < .Owl; Fisher's PLSD P values ranged from <.WO1 to .0002). Although the differences did not reach statistical significance, steadyphase PB CD34+ cells had the highest mean peak shift (2.1 t 0.7) among the various PB CD34+ cells. These changes were confirmed by using three other c-kit antibodies, 17F11, SR-1, and 1DC3, which identify distinct epitopes of c-kit from YB5.B8 (data not shown).
Proliferative Capacity of CD34' Cells
The incidence of CFU-GM in CD34' cells from BM, steady-state PB, G-CSF, Cm, C/T + G-CSF, and C/T + GM-CSF-mobilized PB (209 40, 105 2 50, 183 2 56, 176 ? 62, 271 ? 85, 277 2 43 CFU-GM/1,000 CD34+ cells, respectively) were not significantly different from one another (one-way ANOVA).
The proliferative capacity of CD34+ cells as measured by the generation of nucleated cells and CFU-GM in the pre-CFU assay for up to 21 days in culture is shown in Fig 4,  A and allowing for cells previously removed rather than cumulative production, is shown at each time point.
The number of nucleated cells increased exponentially for 3 weeks, but started to plateau at 4 weeks (data not shown) in all six types of CD34+ cells. The maximum-fold increases in nucleated cell number ranged from 2,520 t 885 (steadystate PB) to 14,333 ? 1,23 14 (Cm + GM-CSF) at day 21.
There was no significant difference in the number of nucleated cells generated among the six types of CD34+ cells at each of the time points studied.
The number of CFU-GM increased exponentially in the first 2 weeks and then leveled off at 3 weeks, although CFU-GM were still present at 4 weeks (data not shown). The number of CFU-GM present at day 21 varied from 1,427 -f 643 (steady-phase PB) to 15,532 2 6,119 (G-CSF) per 1,000 CD34' cells plated. Despite the difference at the start of culture, there was no significant difference in the number of CFU-GM present on days 7, 14, and 21 between the six types of CD34+ cells. On a group-to-group comparison using the Fisher's PLSD, steady-state PB and Cm-mobilized PB showed a significantly lower number of CFU-GM at day 21 than G-CSF-mobilized PB and steady-phase BM (P values range from .0234 to .0449).
DISCUSSION
This is a study of mobilized PB CD34+ cells from four most commonly used PB stem cell mobilization protocols:
Cm, Cm + GM-CSF, Cm + G-CSF, and G-CSF alone. By comparing their phenotype and proliferative capacity with those of steady-phase cells, it provides new information about the nature of mobilized CD34+ cells. This study shows that mobilized CD34' cells are quite similar to steady-state CD34' cells in their expression of activation and lineage markers and in their ability to generate nucleated cells and CFU-GM in a stroma-free HGF-driven liquid culture. How-2935 ever, some important distinctions exist. Firstly, a higher proportion of G-CSF-mobilized CD34+ cells are CD38-than other CD34+ cells. G-CSF-mobilized CD34+ cells also generated more CFU-GM than steady-state PB. Secondly, all four types of mobilized CD34+ cells differ from BM CD34+ cells in their lower expression of c-kit and CD71 and decreased retention of Rh123.
CD34+ cells expressing lineage-associated markers such as CD33 have been shown to be committed progenitors2' and are most probably the cells responsible for the first phase of HR.'4 In contrast, CD34' cells that lack lineage-associated (eg, CD33) or activation antigens (HLA-DR, CD38) are considered to be more primitive hematopoietic cells that are precursors to clonogenic cells and contribute to the late phases of HR. The present study allows us to compare the absolute numbers of CD34+ cell subsets in BM and mobilized PB harvests. In our institution, the mean CD34+ cell yield from a BM harvest is 0.97 t 0.12 X 106kg body weight (1 l allogeneic BM, 23 autologous BM) and based on the findings of this study, 38.5% and 3.9% are CD34'CD33' , CD34'CD38-, respectively. Thus, on average, a BM transplant would contain 0.37 X lo6 CD34+CD33+ cellskg body weight and 0.04 X lo6 CD34+CD38-cellskg body weight. In comparison, the mean CD34+ cell yield in a G-CSF-mobilized PB harvest is 6.3 5 1.4 X 106kg body weight (n = 10) and 28.2% and 12.0% of CD34+ cells are CD33+ and CD38-, respectively. Thus, transplantation with G-CSF-mobilized blood would on average provide 1.77 X lo6 CD34+CD33+ cellskg body weight and 0.76 X IO6 CD34+CD38-cellskg body weight. Similarly, in chemotherapy-mobilized PB, the mean CD34+ 
Steady state BM
Rh 123 retention
Mobilised PB ! ; cell yield i\ 3.62 2 2.48 X IO"/kg body weight (n = 10) with 3.3.5 X 10" CD34'CD33-cells/kg body weight and 0.04 X 10" CD34TD38-cells/kg body weight available for transplantation. Hence, both the lineage-committed (CD34'CD33-) and primitive (CD34'CD3X ) subpopulations are either of equal or increased abundance in mobilized PB compared with steady-state BM.
Bender et a1'5 dcscribcd incrcascd numbers of CD34-lineage' cells in cyclophosphamide mobilized PB. but the present study shows that CD34' cells mobilized by other protocols are also similar. Although the similar expression of other myeloid markers suggests this may not he physiolog- ically signilicant, C/T mobilization yields a higher percentage of CD34'CDM' cclls. The expression of T and B murkers is similar to those previously reported and so is the expression of CD71 in steady-state PB CD34 cell\."' We have also measured the levels o f CD34'CD61' cclls as an indicator of megakaryocytic progenitors. Such a population was identified by flow cytomctry, but sorting based on CD61 expression did not lead to any enrichment of clonogenic megakaryocytic progenitors. Further studies showed that a large number of CD34'CD61' events on flow cytomctry were an artifact caused by adherent platclcts rather than true positivity. Unless sample preparation involves washing with theophylline and adenosine to inhibit platelet aggregation. caution should be exercised when interpreting f o w cytometric data on CD61 expression or other platelet markcrs on CD34' cells.
The question of whether there are LTMRCs in mobili~ed PB rclnains unanswered as there are no in vitro assays folLTMRCs. Recently. the LTClC has been proposed as a candidate LTMRC" and its presence has been described in cyclophosphamide, G-CSF, and C/T + G-CSF-mobilized PB stern in man. However. the levels of LTClC i n these mobilized PB have not been cpantitatcd. In a murine PB mobilization model, primitive stem cells capable o f selrrenewal and competitive repopulation have been shown in mobilized blood at levels approaching that seen in normal BM.'" Phenotypic studies suggest that LTClC arc found in the CD33-, HLA-DR-, and Rh123""" subsets of CD34'
This study shows that such cells are present a t a similar incidence in mobilized PB CD34' cells a s i n \teady-phasc BM and PB.
A recent modification of a stroma-free liquid-culturc system stimulated by a six cytokinc combination has led to the concept of preprogenitors as measured by nucleated cells and CFU-GM generation in CLI~LI~~.'~).''.'' Data presented in this report suggest that CD34' cclls from m o h i l i d PB are capable of generating as many nucleated cells and CFU-GM as those from steady-phase BM and PB. This suggests that there are similar levels and/or proliferative capacity of preFor personal use only. on January 1, 2018. by guest www.bloodjournal.org From progenitors in mobilized PB as in BM. In particular, G-CSF-mobilized CD34+ cells have a significantly higher percentage of CD38-cells and their generation of C m -G M after 21 days is as high as BM CD34+ cells, consistent with the sustained long-term HR seen in patients autotransplanted with G-CSF-mobilized PB.38 Hence, the presence of LTMRC in mobilized PB is supported by clinical observations and by studies in this report. The proof of LTh4RC will have to await transplantation using genetically marked stem cells or allogeneic PB.
Quiescent cell-cycle status is another characteristic often attributed to primitive stem cells. The low CD71 expression and the Rh123d"" status in mobilized PB CD34' cells suggest that there is a high proportion of quiescent cells among them. This requires formal testing of cell-cycle status using tritiated thymidine suicide or BrDU labeling, and such studies are in progress. Steady-state PB C m -G M were ascribed a high cycling status based on a hydroxyurea killing technique,39 but no such studies on mobilized PB have been reported.
The low c-kit expression of mobilized PB CD34+ cells stands out against the findings on other lineage and activation markers that are essentially the same as steady-state CD34+ cells. Because the expression of c-kit on mobilized CD34+ cells is more or less continuous, the low expression represents an overall reduction rather than the presence of a large c-kit negative population. We have previously reported that the majority of CD34+CD19+ cells that are putative B-lymphocyte progenitors are c-kit-." However, in steady-state BM, 46.2% of CD34+ cells are c-kit-, but only 16.1% of CD34+ cells are CD19+, so the presence of CD34+CD19+ cells in steady-state BM could only partly account for the lower c-kit expression among the PB CD34+ cells. Hence, there is a population of CD34+CD19-c-kit-cells that is present in steady-state BM, but not in mobilized PB. The nature of this population is still to be defined and may provide insights into why these cells did not mobilize.
The global reduction of c-kit expression on mobilized CD34+ cells is particularly interesting as the SCF/c-kit relationship is increasingly regarded as more than a simple hematopoietic growth factorhtem cell interaction. The murine SVSld model and the presence of a separate membrane bound form of SCF on hematopoietic stroma both suggest that this ligandreceptor relationship may be a crucial modulator of hematopoietic stromdstem cell interaction. In contrast, a number of classical adhesion molecules such as integrins and L-selectin have been shown to be important mediators of adhesion between BM CD34+ cells and ~t r o m a , '~.~~,~' but their expression on mobilized CD34+ cells was no different from those on steady-phase CD34+ cells (data not shown, manuscript in preparation). Even though the functional status of these molecules is still to be tested, the similarity in their levels of expression suggests that they are not critically involved in the process of mobilization.
The uniformly lower expression of c-kit on CD34+ cells mobilized by different stimuli raises the possibility that modulation of the c-kit/SCF (the former expressed on hematopoietic progenitor cells in BM and the latter on stroma) interaction may be implicated in PB mobilization. Whereas molecules such as C3b may be important in granulocyte mobilization:' the disparate patterns of mobilization of granulocytes and primitive cells make it most likely that primitive cell mobilization occurs via a separate mechanism." The high efficacy of SCF as a mobilization agent in baboon provides further circumstantial e~idence.4~ Craddock et all8 also reported that cyclophosphamide-mobilized murine stem cells did not bind to cultured stroma, whereas repopulating stem cells in BM do. Studies comparing mobilized CD34' cells and BM CD34' cells in adhesion mediated specifically by the c-kit/SCF interaction are in progress to test this speculation. Murine studies suggested that IL-3 and GM-CSF may down-regulate c-kit,-so further studies to determine whether the reduced c-kit expression is caused by blocking or down-regulation by circulating SCF need to be performed. Nevertheless, it is possible that mobilization after C/T and/ or HGF administration may be mediated via a common cytokine network that ultimately alters the expression of c-kit on CD34' cells, thus inducing their egress from the BM. In view of the increasing evidence that mobilized PB containing large number of progenitors lead to faster HR and safer transplantation, these studies have major significance in developing more effective mobilization protocols. 
